Merck KGaA Explores Acquisition of Springworks Therapeutics

On February 10, 2025, Merck KGaA confirmed in Darmstadt that it is engaged in advanced discussions with Springworks Therapeutics, Inc. regarding a potential acquisition. Currently, no legally binding agreement has been established between the two companies.

While discussions are ongoing, Merck KGaA made clear that there is no certainty a transaction will occur. Various critical conditions still need to be fulfilled before any potential acquisition can advance. The company emphasizes that these talks are a response to recent press reports, underscoring the preliminary nature of the negotiations.

Merck KGaA is traded on the Frankfurt Stock Exchange under the DAX index, while Springworks Therapeutics operates in the biopharmaceutical sector. Further updates from Merck will be anticipated as discussions progress.